Clinical Activity of CC-99282, a Novel, Oral Small Molecule Cereblon E3 Ligase Modulator (CELMoD) Agent, in Patients (Pts) with Relapsed or Refractory Non-Hodgkin Lymphoma (R/R NHL) - First Results from a Phase 1, Open-Label Study

CC-99282 is a novel, small molecule CELMoD ® agent that co-opts cereblon to induce targeted degradation of Ikaros/Aiolos, transcription factors critical for development of B-cell malignancies. Lopez-Girona et al. reported that in preclinical models, compared with lenalidomide and other immunomodulatory agents, CC-99282 showed similar immunostimulatory effects and stronger antitumor activity along with robust distribution across multiple tissues. In addition, CC-99282 was shown to exhibit 10- to 100-fold enhanced antiproliferative and apoptotic activity in a range of diffuse large B-cell lymphoma (DLBCL) cell lines, independent of subtype or chemotherapy-resistant status (Lopez-Girona, et al. Hematol Oncol. 2021). Here, we present results from CC-99282-NHL-001, a phase 1, open-label, dose-finding, first-in-human study evaluating CC-99282 in pts with R/R NHL (NCT03930953).